Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study

Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study

Early tumor shrinkage (ETS) and depth of response (DoR) predict favorable outcomes in metastatic colorectal cancer. We aim to evaluate their prognostic role in metastatic pancreatic cancer (PC) patients treated with first-line modified-FOLFIRINOX (FOLFOXIRI) or Gemcitabine + Nab-paclitaxel (GemNab)....

Full description

Bibliographic Details
Main Authors: Caterina Vivaldi, Lorenzo Fornaro, Carla Cappelli, Irene Pecora, Silvia Catanese, Francesca Salani, Andrea Cacciato Insilla, Emanuele Kauffmann, Francescamaria Donati, Giulia Pasquini, Valentina Massa, Niccolò Napoli, Monica Lencioni, Piero Boraschi, Daniela Campani, Ugo Boggi, Davide Caramella, Alfredo Falcone, Enrico Vasile
Format: Article
Language:English
Published: MDPI AG 2019-07-01
Series:Cancers
Subjects:
early tumor shrinkage
depth of response
pancreatic cancer
FOLFOXIRI
gemcitabine plus nab-paclitaxel
Online Access:https://www.mdpi.com/2072-6694/11/7/939

Internet

https://www.mdpi.com/2072-6694/11/7/939

Similar Items